BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025
MWN-AI** Summary
BioSyent Inc. has announced its financial results for the fourth quarter (Q4) and the full year (FY) ending December 31, 2025. The company reported a notable growth trajectory, with total sales reaching CAD 43.05 million for FY 2025, marking a 23% increase compared to the previous year. In Q4 alone, total sales amounted to CAD 9.67 million, a 10% rise from Q4 2024. Canadian pharmaceutical sales also showed positive growth, with a 3% increase to CAD 8.79 million in Q4 and a 13% increase to CAD 37.14 million for the full year.
International pharma sales surged significantly, with Q4 seeing a remarkable 240% increase, and FY revenues growing by 302%, largely attributed to the successful international rollout of Tibelia®. The company's legacy business experienced substantial gains as well, with an increase of 278% in Q4 and 86% for the fiscal year.
BioSyent's EBITDA for FY 2025 rose by 30% to CAD 12.12 million, and net income after taxes also improved by 24% to CAD 9.01 million, reflecting a healthy 21% profit margin. The earnings per share (EPS) for the year were CAD 0.78, up 27% year-over-year.
The company maintained a robust capital position, repurchasing 19,500 shares as part of its normal course issuer bid, and paying out dividends totaling CAD 0.20 per share throughout the year. In March 2026, BioSyent increased its quarterly dividend by 10%, signaling confidence in its financial stability and growth prospects. CEO René Goehrum highlighted the company's strategic investments in core products and the recent acquisition of Oral Science Inc., which enhances BioSyent's oral health portfolio and underscores its commitment to growth and shareholder returns.
MWN-AI** Analysis
BioSyent Inc. has shown promising performance in its financial results for Q4 and FY 2025, presenting a robust double-digit growth trend across various segments. The company reported total sales of CAD 9.67 million in Q4 2025, reflecting a 10% increase year-over-year, while its full-year sales reached CAD 43.05 million, marking a significant 23% growth compared to FY 2024. The substantial growth in international pharma sales, which skyrocketed 240% in Q4 and 302% for the year, indicates successful global market penetration, particularly with the Tibelia® product line.
A key takeaway for investors is BioSyent's continued investment in research and development, particularly in their Tibelia® and FeraMAX® brands, which have become crucial for revenue generation. The company's net income grew by 23% in Q4 and 24% for the year, maintaining a commendable 21% net income margin, which demonstrates effective cost management and operational efficiency. Additionally, the return on equity increased to 24%, showing enhanced shareholder value generation.
Investors should also consider the company’s focus on shareholder returns through quarterly cash dividends, which were recently increased by 10%, signaling confidence in future cash flows. The execution of the Normal Course Issuer Bid (NCIB) further reflects a commitment to returning capital to shareholders and possibly improving earnings per share as fewer shares circulate.
While the financial results showcase BioSyent’s resilience and growth potential, investors should remain cautious of market volatility, especially given the pharmaceutical sector's regulatory challenges. Overall, with a focus on international expansion and strong cash generation, BioSyent presents a compelling investment opportunity for those looking to capitalize on growth in the specialty healthcare sector. Therefore, maintaining a watchful eye on its strategic execution and market dynamics is advisable for potential investors.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MISSISSAUGA, Ontario, March 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2025. Key highlights include:
| (CAD) | Q4 2025 | % Change vs. Q4 2024 | FY 2025 | % Change vs. FY 2024 | ||||
| Canadian Pharma Sales | 8,792,653 | +3 | % | 37,143,783 | +13 | % | ||
| International Pharma Sales | 601,387 | +240 | % | 3,735,959 | +302 | % | ||
| Legacy Business Sales | 277,883 | +278 | % | 2,172,241 | +86 | % | ||
| Total Company Sales | 9,671,923 | +10 | % | 43,051,983 | +23 | % | ||
| EBITDA1 | 2,528,561 | +13 | % | 12,122,756 | +30 | % | ||
| Net Income After Taxes (NIAT) | 1,991,788 | +23 | % | 9,012,232 | +24 | % | ||
| Fully Diluted EPS | 0.17 | +25 | % | 0.78 | +27 | % |
- Return on Average Equity for FY 2025 was 24% as compared to 21% for FY 2024
- During FY 2025, repurchased for cancellation a total of 19,500 common shares under a Normal Course Issuer Bid (NCIB)
- Paid quarterly cash dividends of $0.05 per common share on March 14, 2025, June 13, 2025, September 15, 2025, and December 15, 2025
- Increased quarterly dividend by 10% to $0.055 per common share - paid on March 13, 2026
- Generated $2.4 million in sales in 2025 from international Tibelia® (tibolone) assets acquired in 2024
- Completed acquisition of Oral Science Inc., a Canadian owner and distributor of specialized dental hygiene and oral health products, as announced on March 2, 2026
“We finished 2025 with double-digit overall revenue growth in the fourth quarter with continued growth in our Canadian pharmaceutical business and sizable contributions from our international Tibelia® business and legacy business,” commented Mr. René Goehrum, President and CEO of BioSyent. “For the full year, we are proud to have delivered 23% total Company revenue growth while maintaining a healthy 21% NIAT margin. We continue to invest in our FeraMAX® and Tibella® / Tibelia® products which were significant drivers of revenue and profit growth both in Canada and internationally during the year. We also continued to invest in our growing Inofolic® launch product during the year. Our mature brands, Cathejell®, RepaGyn® and Protect-It® continued to deliver profit and cash flows with narrow ongoing investment. BioSyent’s track record of 62 consecutive profitable quarters and capital-light, cash-flowing business model have enabled us to build a strong balance sheet and afforded us with maximum flexibility in capital allocation decisions. We are pleased to have deployed our hard-earned capital in our recent acquisition of Oral Science Inc. and we are eager to continue to grow this newly-acquired oral health business along with our pharmaceutical business. We will continue to invest in growth and product diversification in both of these businesses while returning capital to shareholders through share buybacks and regular cash dividends. I look forward to sharing our progress throughout 2026.”
The CEO’s presentation on the Q4 and FY 2025 Results is available at the following link: www.biosyent.com/investors/
The Company’s Audited Consolidated Financial Statements and Management's Discussion and Analysis for the fourth quarter and full year ended December 31, 2025 and 2024 will be posted on www.sedarplus.ca on March 19, 2026.
For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit www.tmxmoney.com.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty healthcare company focused on acquiring or in-licensing, marketing and distributing innovative pharmaceutical and oral health products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its Canadian pharma, international pharma, and oral health business units.
As of the date of this press release, the Company has 11,497,447 common shares outstanding.
| BioSyent Inc. | ||||||||||||
| Consolidated Statements of Comprehensive Income | ||||||||||||
| In Canadian Dollars | Q4 2025 | Q4 2024 | % Change | FY 2025 | FY 2024 | % Change | ||||||
| Net Revenues | 9,671,923 | 8,796,684 | 10 | % | 43,051,983 | 35,030,897 | 23 | % | ||||
| Cost of Goods Sold | 2,225,569 | 1,641,735 | 36 | % | 10,088,955 | 7,174,824 | 41 | % | ||||
| Gross Profit | 7,446,354 | 7,154,949 | 4 | % | 32,963,028 | 27,856,073 | 18 | % | ||||
| Operating Expenses and Finance Income/Costs | 4,967,966 | 4,904,040 | 1 | % | 20,933,016 | 18,073,575 | 16 | % | ||||
| Net Income Before Tax | 2,478,388 | 2,250,909 | 10 | % | 12,030,012 | 9,782,498 | 23 | % | ||||
| Tax (including Deferred Tax) | 486,600 | 637,715 | -24 | % | 3,017,780 | 2,512,394 | 20 | % | ||||
| Net Income After Tax | 1,991,788 | 1,613,194 | 23 | % | 9,012,232 | 7,270,104 | 24 | % | ||||
| Net Income After Tax % to Net Revenues | 21 | % | 18 | % | 21 | % | 21 | % | ||||
| EBITDA1 | 2,528,561 | 2,241,112 | 13 | % | 12,122,756 | 9,343,012 | 30 | % | ||||
| EBITDA1 % to Net Revenues | 26 | % | 25 | % | 28 | % | 27 | % |
| BioSyent Inc. | ||||||
| Consolidated Statements of Financial Position | ||||||
| AS AT | December 31, 2025 | December 31, 2024 | % Change | |||
| ASSETS | ||||||
| Cash, cash equivalents and short-term investments | $ | 28,651,823 | $ | 15,940,971 | 80 | % |
| Trade and other receivables | 4,456,562 | 2,906,829 | 53 | % | ||
| Inventory | 6,416,204 | 5,328,086 | 20 | % | ||
| Prepaid expenses and deposits | 187,977 | 201,971 | -7 | % | ||
| Derivative asset | - | 5,790 | -100 | % | ||
| Loans receivable - current | 80,395 | 87,433 | -8 | % | ||
| CURRENT ASSETS | 39,792,961 | 24,471,080 | 63 | % | ||
| Long term investments | 3,293,957 | 10,103,571 | -67 | % | ||
| Loans receivable - current | 61,799 | 141,140 | -56 | % | ||
| Deferred tax asset | 510,932 | 401,166 | 27 | % | ||
| Property and equipment | 982,737 | 1,200,992 | -18 | % | ||
| Intangible assets | 4,797,073 | 5,041,501 | -5 | % | ||
| TOTAL NON CURRENT ASSETS | 9,646,498 | 16,888,370 | -43 | % | ||
| TOTAL ASSETS | $ | 49,439,459 | $ | 41,359,450 | 20 | % |
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||
| CURRENT LIABILITIES | $ | 7,215,608 | $ | 5,405,106 | 33 | % |
| NON CURRENT LIABILITIES | 758,345 | 951,159 | -20 | % | ||
| Long term debt | - | - | 0 | % | ||
| Total Equity | 41,465,506 | 35,003,185 | 18 | % | ||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 49,439,459 | $ | 41,359,450 | 20 | % |
- EBITDA is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization.
A reconciliation of EBITDA to NIAT for the three months, twelve months, and trailing twelve months ended December 31, 2025 and 2024 is provided in the table below:
| Three Months (Q4) Ended December 31 | Full Year (FY) Ended December 31 | ||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||
| EBITDA | 2,528,561 | 2,241,112 | 12,122,756 | 9,343,012 | |||||
| Add: | Interest Income | 187,767 | 260,088 | 809,100 | 1,088,586 | ||||
| Less: | Depreciation - Property, Equipment | (70,964 | ) | (72,113 | ) | (272,299 | ) | (281,220 | ) |
| Amortization of Intangible Assets | (155,498 | ) | (164,207 | ) | (580,192 | ) | (308,728 | ) | |
| Interest Expense | (11,478 | ) | (13,971 | ) | (49,353 | ) | (59,152 | ) | |
| Income Tax Expense | (486,600 | ) | (637,715 | ) | (3,017,780 | ) | (2,512,394 | ) | |
| NIAT | 1,991,788 | 1,613,194 | 9,012,232 | 7,270,104 | |||||
For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web: www.biosyent.com
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
FAQ**
How does BioSyent Inc (BIOYF) plan to sustain its recent growth in Canadian and international pharmaceutical sales, given the impressive increases reported for FY 2025?
With a significant increase in international pharma sales and legacy business contributions, what strategic initiatives will BioSyent Inc (BIOYF) undertake in 20to capitalize on this momentum?
Considering the 10% increase in quarterly dividends for BioSyent Inc (BIOYF), what factors influenced this decision, and how does management foresee balancing dividend payouts with reinvestment in growth opportunities?
Following the acquisition of Oral Science Inc., how does BioSyent Inc (BIOYF) envision integrating this new business within its existing structure, and what are the anticipated synergies?
**MWN-AI FAQ is based on asking OpenAI questions about Biosyent Inc. (TSXVC: RX:CC).
NASDAQ: RX:CC
RX:CC Trading
-0.65% G/L:
$9.15 Last:
1,602 Volume:
$9.19 Open:
